Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of th ...

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely competitive industry is key to ensuring the company's continued growth and ...

Core Insights - Precipio, Inc. reported a non-GAAP Cash Burn/Generated from Operations (CBFO) of $0.3 million for Q2-2024, indicating a positive cash flow for the quarter, partly due to delayed cash collections from Q1 [1] - The company ended Q2-2024 with cash reserves of approximately $1.3 million and management is optimistic about reaching breakeven by the end of the year [2] - CEO Ilan Danieli expressed confidence in the company's financial independence and the intention to avoid dilutive transactions in the future, focusing on long-term shareholder value [3] Company Overview - Precipio is a healthcare biotechnology company specializing in cancer diagnostics, aiming to reduce cancer misdiagnoses through innovative diagnostic products and services [4] - The company's offerings are designed to enhance accuracy, improve laboratory workflow, and ultimately lead to better patient outcomes, thereby reducing healthcare costs [4] - Precipio develops and commercializes proprietary technologies that serve the global laboratory community, with a mission to eradicate misdiagnosis [4]

Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals. About Precipio Forward-Looking Statements NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1- 2024 to $4.4M ...

Core Viewpoint - Precipio, Inc. convened and adjourned its 2024 Annual Meeting of Shareholders due to a lack of quorum, with plans to reconvene on June 21, 2024 [5][8]. Company Information - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [20]. - The company develops technologies in its laboratory to improve diagnostic outcomes and commercializes these as proprietary products for the global laboratory community [20]. Shareholder Voting Information - Shareholders as of April 19, 2024, are encouraged to vote online or by telephone, with voting open until June 20, 2024, at 11:59 p.m. Eastern Time [9][17]. - A quorum requires the presence of a majority of voting power of outstanding shares, which was not met during the initial meeting [8]. - Shareholders who have already submitted proxies do not need to vote again, as their votes will remain valid for the reconvened meeting [16].

During this process, we've realized that there are quite a few shareholders who didn't know whether their shares were voted on or not. You can accomplish this in one of three easy ways that will take no more than 60 seconds: The record date for determining shareholders eligible to vote at the Annual Meeting will remain the close of business on April 19, 2024. Shareholders who have already submitted a proxy do not need to vote again for the reconvened Annual Meeting, as the proxies submitted will remain vali ...

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow June 13, 2024 at 10 a.m. Eastern Time. At the time of this press release, approximately 44% of shares have been voted. For the com ...

In September of 2023, Precipio's pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the quarter. In the following quarter, as previously discussed, due to several operational issues, revenue declined below that point. 2. Change Healthcare hacking & cash impact This rule creates two options to comply: The FDA rule has stipulated that any tests that a lab was operating before the ruling on May 2023 are "grandfathered" into ap ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the quarterly period ended March 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR (203) 787-7888 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delawa ...